FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person *
MARAGANORE JOHN
(Last) (First) (Middle)
C/O HEMAB THERAPEUTICS HOLDINGS, INC.
101 MAIN STREET, SUITE 1220
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
04/30/2026 		3. Issuer Name and Ticker or Trading Symbol
Hemab Therapeutics Holdings, Inc. [ COAG ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series B Preferred Stock   (1)   (1) Common Stock 17,974 (1) D  
Series C Preferred Stock   (1)   (1) Common Stock 17,974 (1) D  
Warrants (Right to Buy)   (2) 03/20/2032 Common Stock 47,476 2.16 D  
Warrants (Right to Buy)   (3) 08/13/2033 Common Stock 90,222 7.07 D  
Warrants (Right to Buy)   (4) 01/28/2036 Common Stock 107,338 6 D  
Explanation of Responses:
1. Each share of Series B Preferred Stock and Series C Preferred Stock is convertible into 22 shares of common stock without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
2. The warrant was granted on March 21, 2022 and is fully vested.
3. The warrant was granted on August 14, 2023 and is fully vested.
4. The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029.
Remarks:
24.1 Power of Attorney
/s/ Mads Nikolaj Behrndt-Eriksen, as Attorney-in-Fact 04/30/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EX-24.1